Beijing Stock Exchange To Roll Out Red Carpet For First Vaccine Firm's Debut
Chinese vaccine developer Beijing Health Guard Biotechnology is seeking to go public on the newly minted Beijing Stock Exchange, against a backdrop of very few biotechs having tried this route to reach public investors.
You may also be interested in...
In immuno-oncology and beyond, Chinese investors are setting their sights on new targets in the biopharma arena.
Five Chinese bioventures have raised more than $70m from venture capital and private equity funds since late May.
With the first half of 2022 ending, two Chinese developers of innovative drugs - antibody specialist Chongqing Genrix Biopharmaceutical and Suzhou Teligene, which focuses on small molecules, are looking to go public on Shanghai’s STAR Market, ending a recent drought of biopharma listings.